Novorapid Flexpen (Insulin Aspart)

Novorapid Flexpen is a rapid‑acting insulin that works within the carbohydrate‑digestion pathway to control blood glucose levels.

• Type 1 diabetes mellitus: provides mealtime insulin coverage to lower post‑prandial glucose.
• Type 2 diabetes mellitus: supplements basal insulin or oral agents for post‑meal glucose control.
• Postprandial glucose control: rapidly reduces glucose excursions after meals.

• Insulin aspart binds to insulin receptors on muscle, fat and liver cells, activating the receptor’s tyrosine‑kinase activity. This triggers intracellular signaling that promotes glucose uptake into cells and suppresses hepatic glucose production, resulting in lowered blood glucose concentrations.

Novorapid Flexpen may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Hypoglycaemia: low blood sugar episodes, especially if meals are missed or delayed.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Lipodystrophy: localized changes in fat tissue with repeated injections.
• Weight gain: modest increase in body weight with chronic use.

Serious or Rare Side Effects

• Severe hypoglycaemia: prolonged low blood sugar requiring assistance.
• Allergic reaction: rash, hives, or swelling that may indicate anaphylaxis.
• Edema: swelling of extremities due to fluid retention.
• Unexplained cardiovascular events: chest pain or palpitations.

When using Novorapid Flexpen, consider the following safety measures:

• Dose titration: adjust based on blood glucose monitoring and physician guidance.
• Meal timing: coordinate injection with carbohydrate intake to avoid hypoglycaemia.
• Renal or hepatic impairment: monitor closely as clearance may be altered.
• Pregnancy and lactation: use only if the benefits outweigh potential risks.
• Storage: keep the pen refrigerated at 2‑8 °C, protect from light, and do not freeze.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Novorapid Flexpen can interact with several drug classes, requiring awareness of the interaction level.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.
• MAO‑inhibitors: can potentiate insulin’s glucose‑lowering effect.

Moderate Interactions (Monitor Closely)

• Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides): increase risk of hypoglycaemia.
• Corticosteroids: may raise blood glucose, requiring insulin dose adjustments.
• Thiazide diuretics: can affect glucose tolerance and insulin sensitivity.
• Alcohol: enhances insulin absorption and may precipitate hypoglycaemia.